Work

Supplementary Figure 3 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

Year: 2023

Type: supplementary-materials

Abstract: Relative changes (mean and standard deviation) in γ-H2AX expression in CD3+ (A) and CD14+ (B) cells and by microscopy (C) before and after treatment. Figure S2C shows representative images of γ-H2AX foci incidence in PBMCs from one patient pre-treatment (C1D1), cycle 1 day 2 (C1D2), cycle 1 day 3 (C1D3), and cycle 2 day 1 pre-treatment (C2D1). Green, γ-H2AX; red, DNA stained with propidium iodide.

DOI: 10.1158/1078-0432.22461474.v1

Authors: Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361920422

Cites:

Cited by:

Related to: 10